Tarapeutics Science Inc.

Chinese Academy of Sciences

Precedo Pharmaceuticals Co., Ltd

Wuhan Construction Engineering Group Co., Ltd.

Hefei Gracevo Bio-medicine Co., Ltd

Hefei Cosource Pharmaceutical Co., Ltd.

Li Wang

Yi Yang

Cheng Chen

Jing Liu

Qingsong Liu

Beilei Wang

Wenchao Wang

Chen Hu

Ziping Qi

Aoli Wang

Hong Wu

Shuang Qi

Fengming Zou

Kailin Yu

Shuai Wang

Wenxiang Li

Tong Lu

Wei Wang

Junjie Wang

Ming You

Qingwang Liu

Wen Chao Wang

Wenliang Wang

Wei Yang

Chen Liu

Xi Li

Tao Ren

Mingzhao Wang

Aixun Wang

Yunjie Dong

Xiaolong Yang

Yun Wu

Juan Liu

Bo Wang

Tingting Zhang

Hui Wang

Jiaxin Wu

Zongru Jiang

Ao Li Wang

Xixiang Li

Yongfei Chen

Xiaofei Liang

Chen Qian

Keyang Wu

Qing Wang Liu

Qing Song Liu

Feng Ming Zou

Zhenquan Hu

Wen Liang Wang

Zi Ping Qi

Bei Lei Wang

Zheng Zhao

Xin Li

Shenghao Li

Jun He

Jianhui Wu

Yuanbang Ge

Qingshan Meng

Yangjun Xu

Zongyou Hu

Zhendong Du

Jiang Yan Cao

Bangfeng Xi

Ziping Q

Zhizhen Wu

Zong Ru Jiang

Xuesong Liu

Wenhui Xiong

Feng Li

Feiyang Liu

Xiaochuan Liu

Qianmao Liang

Fengchao Lv

Qiang Wang

Xiao Fei Liang

Taoshan Jiang

Xi Xiang Li

A multi-tower linkage type aerial hoisting platform includes: four tower crane body lifting/lowering parts respectively disposed in an outer periphery of a building to form a rectangle through enclosure, and including a tower crane body and a self-climbing lifting/lowering system that is capable of climbing or descending step by step along the tower crane body; four tower-crane-body-connected support beams, respectively disposed on two opposite self-climbing lifting/lowering systems, where a hoisting platform enclosed by the tower-crane-body-connected support beams is driven by the self-climbing lifting/lowering systems to move up and down synchronously; and four movable tower crane bases, respectively disposed at lower ends of the four tower crane body lifting/lowering parts, including movable chassis that are used as movable supports with a variable platform angle and support parts disposed on the movable chassis, where four corners of the support parts are respectively provided with rotary drilling fastening parts.

Multi-tower linkage type aerial hoisting platform

A multifunctional construction site cleaning robot and a cleaning method using the same are provided. The robot includes a chassis part; a bottom rotatable function part, including a sweeper unit, an iron remover unit, a leaf remover unit and a cutter unit; a debris treatment part, including a compression unit, a debris container and a pulverizing unit; a container exchange part, including a movable gripper unit and openable containers, the openable containers being configured to contain sundries collected by the sweeper unit and the iron remover unit; a spray part, configured to prewet or dedust a construction site; and a water transfer part, including an extensible water discharging unit and an extensible water pumping unit, the extensible water discharging unit being configured to pump accumulated water, and the extensible water pumping unit being configured to pump accumulated water from a bottom of a pit to the ground.

Multifunctional construction site cleaning robot and cleaning method using same

Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.

Pan-KIT kinase inhibitor having quinoline structure and application thereof

Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.

MST1 kinase inhibitor and use thereof

Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFRα and/or PDGFRβ kinase activity.

Pyrazole derivatives and use thereof

A rotary digging drill includes three disk drills arranged in ascending order of diameter, each with a cavity therein. The disk drill includes two circular ring seats arranged side by side, multiple toothed digging buckets disposed at peripheries of the two circular ring seats, and ring gear racks respectively disposed on inner sides of the two circular ring seats. Adjacent ones of the disk drills have the toothed digging buckets facing opposite directions, and the disk drills all rotate in a direction facing a large opening, enabling adjacent two of the three disk drills to rotate in opposite directions. The rotary digging drill further includes three disk drill supports that match the three disk drills in quantity and are configured to support and drive the three disk drills.

Rotary digging drill and amphibious tunnel construction robot using same

The present application relates to a compound serving as a selective PI3Kδ kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R, R, R, R, Rand Rare as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3Kδ kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3Kδ, as well as a use thereof.

Selective PI3Kδ inhibitor and use thereof

Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 activity in a subject.

Indazole kinase inhibitor and use thereof

The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.

Pan-RAF kinase inhibitor and use thereof

The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR&#x3b1; and/or PDGFR&#x3b2; kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject. 

Pyrimidine derivative kinase inhibitors

The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase). 

Inhibitor of FLT3 kinase and use thereof

The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases. 

Selective C-KIT kinase inhibitor

The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation. 

Kinase inhibitor against wild-type and mutant EGFR

The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same. 

Irreversible bruton's tyrosine kinase inhibitor

An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2 is provided herein. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat a cancer or precancerous condition related to EZH2 activity. 

EZH2 inhibitor and use thereof

Growing community of inventors

Anhui, China

Li Wang